Semaglutide, tirzepatide equally effective in cardiometabolic HFpEF
Semaglutide is as good as tirzepatide in the treatment of patients with cardiometabolic heart failure with preserved ejection fraction (HFpEF), with both drugs yielding substantial reduction in the risks of cardiac hospitalization and mortality compared with sitagliptin, as reported in a study.
Semaglutide, tirzepatide equally effective in cardiometabolic HFpEF
25 Oct 2025